Rita Tibbs, MD
Anatomic Pathology & Clinical Pathology · Houston, TXNPI 1598727232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 50.2% of the total. Reporting peaked in 2023 at $269 and has fallen 69.2% since, to $83 in 2025.
Across 19 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$278
- Urogen Pharma, Inc.$81
- Boston Scientific$68
- Johnson & Johnson$42
- Merck$23
- Astellas Pharma US Inc$22
- plus $39 from 2 others
What the payments were for
- Food & beverage$554100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 9 | $278 |
| Urogen Pharma, Inc. | 3 | $81 |
| Boston Scientific | 2 | $68 |
| Johnson & Johnson | 1 | $42 |
| Merck | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Bayer | 1 | $20 |
| Abbott | 1 | $19 |
How this compares
$554 in reported general payments places this provider in the 80th percentile of 736 anatomic pathology & clinical pathology providers in Texas.
See all anatomic pathology & clinical pathology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other anatomic pathology & clinical pathology in Houston
- Rabia ShafiHouston$519K
- Jason GregorioHouston$238K
- Sanam LoghaviHouston$94K
- Savitri KrishnamurthyHouston$80K
- Thomas LohmannHouston$30K
- Aysegul SahinHouston$29K
- Lillian GaberHouston$23K
- Ken YoungHouston$23K
- Hong ZhangHouston$22K
- Michelle WilliamsHouston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.